CEO SUMMARY: Having opened its CLIA-licensed laboratory in Huntington Beach, California, Agendia, Inc., becomes the newest competitor to enter the market for breast cancer testing. Its proprietary assay looks at 70 genes to assess the risk of recurrence. The company expects to collaborate with local pathologists, as its test requires fresh tissue and can provide […]
New Lab Player Launches In Breast Cancer Market
Its proprietary assay evaluates 70 genes to predict odds of breast cancer recurrence
- By Robert Michel
- > From the Volume XVI No. 11 - August 10, 2009 Issue
- Tags: Anatomic pathology, breast cancer test, breast cancer testing, breast cancer tests, cancer testing, cancer tests, cap, clia, companion diagnostic, Companion diagnostics, diagnostic assays, gene test, genetic diagnostic, genomics, in vitro diagnostic, lab test, lab tests, laboratory test, laboratory testing, laboratory testing companies, Medicare, molecular assay, molecular assays, molecular pathology, myriad genetic, myriad genetics, pathologists, Pathology group, personalized medicine, tests for breast cancer
